reason report
bottom line believ strongli posit advoc
anca-associ vascul aav outcom firmli place
investor radar howev addit data catalyst expect
momentum behind could continu
view start data sub-nephrot
focal segment glomerulosclerosi fsg may way
address differ rare diseas signific unmet need
consequ may hold attract econom implic meanwhil
management guid nda submiss aav follow
submiss ema partner vifor pharma later --
transit becom commercial-stag compani may
right around corner updat model reflect
financi result reiter op increas pt lower opex
aav nda file file follow later
believ partner vifor pharma final stage prepar
nda submiss base time guidanc could envis
market entri us eu territori accord
sale field forc may suffici effect commerci
avacopan target rheumatologist nephrologist account
us market per prior agreement vifor retain right avacopan
ex-u management anticip file follow later
believ may also lead market entri recal stand receiv
royalti teen aggreg net sale vifor territori
although clariti avacopan price remain tbd believ
strength advoc data link could lead favor price
reimburs coverag
data cascad -- total -- could keep excit name
investor despit prolong weak much
advoc data mark turn point investor
interest question sinc rang commerci prospect
aav promis pipelin guid data readout
think momentum continu start
data may begin unlock valu second
accolad glomerulopathi nephrot
syndrom fsg round data catalyst
bull case wherein readout posit could way
pursu differ diseas span gamut ultra-orphan
 medium rare hs pt popul view
today close price repres heavili probability-weight
opportun follow-on program
blend revenu multipl
net debt total capit
year price history/av daili volume mil
compani inform svb leerink llc research
revenu
pleas refer page import disclosur price chart analyst certif
model adjust report revenu ep
respect revenu
respect look ahead nimbl salesforc
aav potenti concentr commerci effort
 rheumatolog nephrolog dermatolog lead us believ
opex growth may gradual prior project
accord result lower near-term opex
long-term opex reduc vs prior estim
chang result increas pt
rate share outperform clinical-stag biotechnolog compani leverag
oral administ small molecul inhibit chemokin chemoattract receptor much
ccxi valuat hing lead compound avacopan formerli potent inhibitor
receptor evalu multipl mid-to-l stage clinic trial
see posit advoc data anca-associ vascul aav de-risk
asset well valid druggabl target behind aav potenti posit outcom
follow-on indic glomerulopathi hidraden suppurativa hs may
render avacopan pipelin within drug despit mani uncertainti unknown
complement biolog believ alxn op success set import preced
sinc chemokin complement system far-reach implic human health
avacopan success could lead posit read-through ccxi earlier-stag asset
asset long term de-risk avacopan could
lead investor appreci ccxi proprietari platform may eventu tap
preval competit indic inflammatori bowel diseas ibd oncolog
valuat limit ccxi orphan program
deriv one-year pt base blend dcf analysi revenu
multipl analysi assign valu probability-weight sale avacopan po
anca-associ vascul aav glomerulopathi hidraden
suppurativa hs sale po focal segment glomerulosclerosi
fsg addit indic clinic asset earlier-stag candid
repres upsid estim matur clinical-stag compani de-risk aav
program use discount rate termin growth rate impli market cap
clinical-stag compani risk includ clinic regulatori financi
lead asset avacopan add signific binari risk head data readout even
though evalu multipl indic guarante program
understand complement system diseas still evolv success
particular indic may translat success indic
clinic risk associ clinic candid
collabor licens revenu
total incom expens
chang cash
proce common stock
proce convert note/debt
proce warrant
discount rate/cost equiti
